Primary endpoint
The difference of success rate in reducing QUIP-RS at 8 weeks, was of 7% between groups (one-sided upper 90% CI 27%), with 8/19 patients experiencing success in the clonidine group (42.1%) and 7/20 in the placebo group (35.0%) in the ITT population. In the PP population, the proportion difference was of 10% (one-sided upper 90% CI 30.5) with 42.1% of success in the clonidine group and 31.6% in the placebo group.